Circadian Reset
78
상호작용
3
5,400
intermediate
May 17, 2026
개요
The Circadian Reset protocol addresses disrupted sleep-wake cycles through a multi-target approach that normalizes both the circadian oscillator and the downstream hormonal rhythms it controls. DSIP serves as the direct sleep promoter, facilitating delta-wave sleep onset and reducing the hyperarousal that prevents circadian entrainment. In shift workers and individuals with delayed sleep phase, DSIP helps establish a consistent sleep onset time by providing a reliable pharmacological "sleep gate" that the body can then entrain around. Epithalon''s role in this stack extends beyond its telomere-related effects to its documented influence on pineal gland function. Professor Khavinson''s research demonstrated that Epithalon normalizes melatonin production in elderly patients whose pineal glands had calcified and atrophied with age. By restoring melatonin synthesis to youthful levels, Epithalon helps re-establish the master circadian signal that synchronizes peripheral tissue clocks throughout the body. The 10-day evening administration cycle targets the pineal gland during its active phase (melatonin synthesis peaks at night), providing both immediate melatonin support and long-term pineal restoration. Morning Selank administration addresses the cortisol-awakening response and daytime alertness — the other half of circadian health. By reducing anxiety and normalizing stress hormones during the day, Selank prevents the evening cortisol elevation that is one of the most common causes of sleep-onset insomnia. Proper daytime alertness (supported by healthy cortisol rhythm) is as important to circadian health as nighttime sleep — the system requires contrast between active and rest phases. This stack is intermediate-level because it requires coordinated timing across three administration windows and includes the cyclical Epithalon component that requires scheduling awareness.
용량 프로토콜
100 mcg
1회 용량당
5,000 mcg
1회 용량당
300 mcg
1회 용량당
목표 및 증거
경고
- Epithalon and DSIP were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — not legal to compound yet. This combination targets both pineal function (Epithalon/DSIP) and daytime stress (Selank). Experimental protocol.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.